HCM
CTMX icon

Highbridge Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Highbridge Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-34,627
Closed -$598K – 1309
2017
Q1 		$598K Buy
34,627
+20,246
+141% +$266K 0.01% 818
2016
Q4 		$158K Buy
+14,381
New +$174K ﹤0.01% 1164

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Highbridge Capital Management's CTMX Position: Q2 2017 in Review

Highbridge Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2017, closing a stake of 34,627 shares — an estimated $598K sold.

Highbridge Capital Management first reported a position in CTMX in Q4 2016 and held it in 2 quarters. The position peaked at $598K in Q1 2017. 90 funds tracked by Wall St. Rank hold CTMX as of Q2 2017.

  • Highbridge Capital Management reported no remaining CytomX Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 34,627 CytomX Therapeutics shares in Q2 2017, an estimated $598K.
  • Highbridge Capital Management first reported a position in CytomX Therapeutics in Q4 2016 and held it in 2 quarters.
  • Highbridge Capital Management's CytomX Therapeutics position peaked at $598K in Q1 2017.
  • 90 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.